Epidarex Capital, a leading early stage life science firm, is delighted to announce the addition of two veteran life science professionals to its transatlantic team. Dr. Henning Steinhagen has joined as a Venture Partner and will support Epidarex in building exciting life science companies around…
No inflammation observed in ten patients dosed in Phase 1b trial with new intravitreal APL-2 drug product from modified manufacturing process CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat…
Apellis to receive up to $120 million in upfront and near-term milestone payments, with the potential for additional payments subject to mutual agreement Apellis retains exclusive worldwide commercial rights to APL-2 in all indications WALTHAM Mass., and CRESTWOOD, Ky., Feb. 28, 2019 (GLOBE NEWSWIRE) —…
Edinburgh, Scotland, 28th February, 2019 – AdoRx Therapeutics, a UK based drug discovery company, today announced that it has entered into a strategic collaboration with Johnson & Johnson Innovation LLC* and the Lung Cancer Initiative at Johnson & Johnson to develop novel therapeutics for the…
New designation now includes all PNH patients CRESTWOOD, Ky. and WALTHAM, Mass., – Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that the U.S. Food and…
CRESTWOOD, Ky., and WALTHAM, Mass., – Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel therapeutic compounds to treat diseases through inhibition of the complement system, today announced that its C3 complement inhibitor, APL-2, has been granted orphan drug designation…
Represents New Hope for Repairing Challenging Bone Fractures Aberdeen, UK, January 31, 2019– SIRAKOSS Ltd, a developer of nanosynthetic bone graft substitutes to transform the treatment of spinal fusions and bone defects, announced today it has been granted CE Mark clearance in the European Union…
We are pleased to welcome Terri Burke to the Epidarex team. Terri joins the Epidarex transatlantic team as a Venture Partner and will focus on developing and executing our upcoming funds’ MedTech strategy. From her base in the U.S., Terri will be sourcing new investment…
The following article was published in The Times on December 26, 2018 Mention the word “charity” to most people and they’ll think of the grey-haired old lady with the sweet smile standing behind the second-hand shop counter. Yet today’s charities rarely fit into that clichéd…
New investors Alsa Holdings and UCL Technology Fund join Epidarex Capital Proceeds will allow IGEM to continue development of IgE therapeutic antibody portfolio and novel IgE-based platform technology London, November 30th, 2018 – IGEM Therapeutics (IGEM or “the Company”), an immuno-oncology company developing novel immunoglobulin…